GlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
How to Invest in Global Wide Moat Stocks
The Morningstar Global Wide Moat Focus Index has global exposure, unlike the Morningstar International Moat Index (MOTI).
How Saudi Arabia’s Bond Sale Affects US Treasury Bonds
Saudi Arabia has also been involved in the sale of US Treasuries. The country is the 15th-largest holder of US Treasury bonds in the world.
Analyzing Johnson & Johnson’s 1Q18 Profitability
Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.
Introducing Danaher: A Diversified Healthcare Company
Danaher is a diversified conglomerate with a market cap of ~$56 billion. Its customers are mostly professionals and organizations rather than retail consumers.
Align Technology Traded at Its 52-Week High in September
Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.
WTX101: A Superior Treatment for Wilson Disease
WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.Healthcare Why enterprise solid-state drives are a growth driver for Micron
Micron’s solid-state storage business ranges from hard disk drive (or HDD) replacements with solid-state drives (or SSDs) for clients to enterprise-class storage solutions.
Novartis Receives 2 Breakthrough Therapy Designations in January
In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.
The Biggest Detractors for Einhorn’s Greenlight in 2018
Overall, in 2018, the most significant contributors to Greenlight Capital’s gains included Micron Technology (MU) and Twitter (TWTR).
Chesapeake Energy: ‘Buy’ or ‘Sell’ after Its Q4 Earnings?
On February 27, Chesapeake Energy might report an adjusted net income of $0.18 per diluted share based on analysts’ consensus estimates.
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
Hedge Funds’ Net Long Positions in US Natural Gas
Hedge funds decreased their net bullish positions in US natural gas futures and options 1.9% to 186,799 on June 12–19.
Johnson & Johnson’s Erleada Approved by Health Canada
On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada.
CVS versus Walgreens: Which Has a More Diversified Business Model?
CVS generates close to 70% of its annual sales by offering a full range of pharmacy benefit management services.
Wall Street Looks at Sales Forecasts for Mylan’s Fulphila
According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.
Nike’s Target Markets: Everything You Need to Know
Nike (NKE) faces some challenges in its target markets. In the US, economic growth rates have tapered down, and the trade war could affect its China market.
Anadarko Petroleum’s Free Cash Flow Forecast
Anadarko Petroleum’s capex has mainly been showing an increasing trend since the first quarter of 2016. The free cash flow has been negative.
S&P 500 Index Nears Record High amid Earnings Season
The S&P 500 Index, represented by the SPDR S&P 500 ETF (SPY), rose 0.3% on October 23, nearing the all-time high it saw in July.
Analysts’ Recommendations for Haemonetics and Peers in March 2018
In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.
Entering Migraine Market Won’t Be Easy for Novartis, Amgen
Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.
What’s Gilead Sciences’ Valuation?
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
Analyst Recommendations for Varian Medical Systems before 1Q18
Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.Healthcare Why dividend recapitalization is the sweet spot for leveraged loans
While M&A activity was still below market prospects, demand for dividend recapitalization deals was mostly strong last week.
How Merck’s Zepatier and Isentress Are Positioned after 2Q17
In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.
Mylan’s Humira Biosimilar Opportunity in Europe
On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.
A Brief Look at Abbott’s Alere Integration Progress and Recovery
Alere’s integration synergies in 1Q18 were delivered through strong performance of the company’s Rapid Diagnostics business.
Teva’s Share of the US Generics Market Could Boost Its Stock
Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.
How Merial Contributes to Sanofi’s Growth
Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.
Extra Space Storage Continues to Enhance Shareholder Wealth
Since its conversion to an REIT in 2004, Extra Space Storage (EXR) has paid regular quarterly cash dividends to its shareholders.Consumer Overview: Ambre Energy—a coal and oil shale export company
Ambre Energy was founded in June 2005. It’s an Australian-American coal and oil shale company. The company’s Australian headquarters are located at Brisbane. The head American office is located at Salt Lake City, Utah. The company operates in three business lines—U.S. coal export infrastructure, international coal marketing and trading, and U.S. thermal coal production.
How Is UNH’s Optum Business Positioned in the Industry?
UnitedHealth Group is, by revenue, the largest healthcare company in the world.
Discussing Abbott’s Market Position and Growth Prospects in China
China contributes significantly to Abbott’s Established Pharmaceuticals division, which registered sales of ~$1.1 billion, representing year-over-year growth of ~10.0%.
Scribe Therapeutics and Biogen $415 Million Deal Is Underway
Scribe Therapeutics, led by a team of CRISPR pioneers, is partnering with Biogen for a deal projected to be worth millions.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
What Else Could Drive Gilead’s Long-Term Growth?
In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.Financials The big 3 ETF providers in the US—iShares, SPDR, and Vanguard
In the U.S., Blackrock (BLK), State Street GA (STT), and Vanguard are the top three ETF providers. They have a 40.1%, 22.3%, and 20.7% market share, respectively.
Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth
On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.
A Look into Merck’s Immunology and Oncology Portfolio
In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Teva’s Copaxone Maintains Market Share amid Intense Competition
In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.